pasmc

Iptakalim hydrochloride 是一种亲脂性的对氨基化合物，是 ATP 敏感的钾通道的开放剂，也是含α4β2的烟碱乙酰胆碱受体拮抗剂。它也是一种 K(ir) 6.1 SUR2B 激活剂，可通过保护内皮功能减轻大鼠缺氧引起的肺动脉高压。

MIF098 是一种巨噬细胞迁移抑制因子 (MIF) 拮抗剂。MIF098，抑制与 SLE 相关的肺动脉高压，抑制肺平滑肌细胞(PASMC)增殖和迁移。MIF098 可用于研究特发性肺动脉高压。

Cefminox (Sodium) is a new cephamycin antibiotic possessing a D-amino acid moiety derived from D-cysteine at the C-7B side chain. Cefminox is active against a wide range of bacteria, especially Gram-negative and anaerobic bacteria. Cefminox shows excellent in vivo efficacy (ED50) which is higher than would be expected from its in vitro activity (MIC). Moreover, cefminox possesses more potent activity in suppression of bacterial regrowth than other cephems[1]. Cefminox (Sodium) was the most active beta-lactam, with an MIC at which 50% of isolates are inhibited (MIC50) of 1.0 microg ml and an MIC90 of 16.0 microg ml. Cefminox was especially active against Bacteroides fragilis (MIC90, 2.0 microg ml), Bacteroides thetaiotaomicron (MIC90, 4.0 microg ml), fusobacteria (MIC90, 1.0 microg ml), peptostreptococci (MIC90, 2.0 microg ml), and clostridia, including Clostridium difficile (MIC90, 2.0 microg ml)[2]. The use of a single preoperative dose of cefminox was similar in efficacy to 3 doses of cefoxitin administered every 4 hours, and that the serum and tissue concentrations attained provide adequate antibiotic coverage[3]. Moreover, cefminox as a dual agonist of IP (Prostacyclin receptor) and PPARγ (peroxisome proliferator-activated receptor-gamma) that significantly inhibits PASMC proliferation by up-regulation of PTEN (phosphatase and tensin homolog) and cAMP ( cyclic adenosine monophosphate), suggesting that it has potential for treatment of PAH(pulmonary arterial hypertension)[4].